Indivior PLC (LON: INDV)

Market Cap	1.15B
Revenue (ttm)	881.89M
Net Income (ttm)	-2.24M
Shares Out	126.15M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	7.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,110
Open	904.50
Previous Close	914.50
Day's Range	904.50 - 938.50
52-Week Range	554.50 - 1,770.00
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 14, 2025

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUB...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 1,164
• Stock Exchange: London Stock Exchange
• Ticker Symbol: INDV

Financial Performance

Financial numbers in USD